Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis.
Carcinoma, Hepatocellular
/ therapy
Humans
Liver Neoplasms
/ therapy
Chemoembolization, Therapeutic
/ methods
Phenylurea Compounds
/ adverse effects
Quinolines
/ therapeutic use
Immune Checkpoint Inhibitors
/ therapeutic use
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Combined Modality Therapy
hepatocellular carcinoma
lenvatinib
programmed cell death protein-1 inhibitors
transarterial chemoembolization
unresectable
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
17
07
2024
accepted:
15
08
2024
medline:
17
9
2024
pubmed:
17
9
2024
entrez:
16
9
2024
Statut:
epublish
Résumé
Locoregional treatment combined with systemic therapy is expected to play a synergistic anticancer role. We conducted this systemic meta-analysis to examine the efficacy and safety of transarterial chemoembolization (TACE) plus lenvatinib with or without programmed cell death protein-1 (PD-1) inhibitors (TLP group) compared with TACE + lenvatinib (TL group) for unresectable hepatocellular carcinoma (uHCC). From the inception date to April 2024, the data from PubMed, EMBASE, the Cochrane Library, Ovid, Web of Science, and Clinical Trials. gov were used for meta-analysis. All clinical outcomes of interest included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). The hazard ratio (HR) and risk ratio (RR) with 95% confidence intervals (CI) were used to measure the pooled effect. This study included 10 retrospective cohort studies, including 1128 patients. The OS (HR=0.51; 95% CI: 0.43-0.60, The TLP group had better efficacy for uHCC than that of the TL group, with acceptable safety. PROSPERO, identifier (CRD42023420093).
Sections du résumé
Background
UNASSIGNED
Locoregional treatment combined with systemic therapy is expected to play a synergistic anticancer role. We conducted this systemic meta-analysis to examine the efficacy and safety of transarterial chemoembolization (TACE) plus lenvatinib with or without programmed cell death protein-1 (PD-1) inhibitors (TLP group) compared with TACE + lenvatinib (TL group) for unresectable hepatocellular carcinoma (uHCC).
Methods
UNASSIGNED
From the inception date to April 2024, the data from PubMed, EMBASE, the Cochrane Library, Ovid, Web of Science, and Clinical Trials. gov were used for meta-analysis. All clinical outcomes of interest included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). The hazard ratio (HR) and risk ratio (RR) with 95% confidence intervals (CI) were used to measure the pooled effect.
Results
UNASSIGNED
This study included 10 retrospective cohort studies, including 1128 patients. The OS (HR=0.51; 95% CI: 0.43-0.60,
Conclusion
UNASSIGNED
The TLP group had better efficacy for uHCC than that of the TL group, with acceptable safety.
Systematic review registration
UNASSIGNED
PROSPERO, identifier (CRD42023420093).
Identifiants
pubmed: 39281676
doi: 10.3389/fimmu.2024.1466113
pmc: PMC11392794
doi:
Substances chimiques
lenvatinib
EE083865G2
Phenylurea Compounds
0
Quinolines
0
Immune Checkpoint Inhibitors
0
Types de publication
Meta-Analysis
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1466113Informations de copyright
Copyright © 2024 Chen, Jia, Li, Cui, Wang, Zhang, Bian and Luo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.